Does ELTX pay a dividend and is it safe?

Elicio Therapeutics Inc. (ELTX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / ELTX / dividends

MREO (37) BMEA (30) ATNM (43) DWTX (38) ⌘ Pro Terminal →

Elicio Therapeutics Inc. (ELTX) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.68 -4.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.66

Elicio Therapeutics Inc. (ELTX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $45.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ELTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Elicio Therapeutics Inc. (NASDAQ: ELTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.68 (-4.00% 1D, market cap $45.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ELTX ranks #867 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ELTX compare to MREO and BMEA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELTX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M) and BMEA (Biomea Fusion Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M). Among the 5-stock peer group, ELTX leads on earnings multiple (N/A) while DWTX leads on capital efficiency (-32.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELTX?

▼

Per ELTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601485), Elicio Therapeutics Inc. generated $105.6M in revenue (-16.2% YoY), -$39.6M in net income, and -$37.0M in free cash flow against $25.9M in total assets and $9.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.66 (-0.91%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY ELTX SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.77-11.3% Next Q

Q2 (-2Q)

Grade E$1.57+16.6% Next Q

Q3 (-1Q)

Grade E$1.83-8.2% Next Q

Current

Grade E$1.68-10% Hist 90D α

Trajectory: E (36) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELTX currently carries a cautious 28/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.01) and Max Pain ($1.76) forces dealer call-delta covering toward $16.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ELTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELTX)

✓Walkthrough of ELTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ELTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.40%⚡ TESTING RESISTANCE

2026-11-03O $1.75H $1.75L $1.68C $1.68VOL 183.9K

RES: $1.77SUP: $1.24SMA50: $2.01SMA200: $6.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELTX Butterfly Map → + Track ELTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ELTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ELTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELTX)

Health Care Rank #867 of 1016 ⚔️ MREO vs ELTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELTX vs. MREO, BMEA, ATNM, DWTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Elicio Therapeutics Inc. (ELTX) ranks #867 by composite RQD confidence (28/100, grade E) and #760 by equity capitalization ($45.5M). Within this direct 5-issuer industry benchmark cohort, ELTX leads on earnings valuation at N/A trailing P/E, while DWTX leads on capital efficiency and profitability with -32.3% ROIC and — gross margin. ATNM currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ELTX at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ELTX ACTIVE Elicio Therapeutics Inc.	E	28/100	—	—	-35.0%	-4.00%	$45.5M	Benchmark Subject
MREO Mereo BioPharma Group plc	D-	37/100	—	—	-35.0%	-4.08%	$46.2M	/mreo-vs-eltx →
BMEA Biomea Fusion Inc.	E	30/100	—	—	-35.0%	+2.68%	$46.4M	/bmea-vs-eltx →
ATNM Actinium Pharmaceuticals Inc. (Delaware)	D-	43/100	—	—	-35.0%	-3.27%	$46.5M	/atnm-vs-eltx →
DWTX Dogwood Therapeutics Inc.	D-	38/100	—	—	-32.3%	+4.07%	$43.5M	/dwtx-vs-eltx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001601485

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elicio Therapeutics Inc. (ELTX) reported GAAP revenue of $105.6M (-16.2% vs. FY2024 revenue of $126.0M , and +5.5% cumulative change since FY2023) , GAAP net income of -$39.6M, operating cash flow of -$37.0M, and free cash flow of -$37.0M (+0.5% YoY). On the balance sheet, ELTX closed FY2025 with $25.9M in total assets against $9.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$105.6M	-$39.6M	-$37.0M	-$37.0M	$25.9M	$9.4M
FY2024 (FY)	2024-12-31	$126.0M	-$51.9M	-$37.1M	-$37.2M	$28.2M	$20.0M
FY2023 (FY)	2023-12-31	$100.1M	-$35.2M	-$32.7M	-$32.7M	—	—

3. ELTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ELTX compare to MREO and BMEA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ELTX?

Where is ELTX trading relative to its 50-day, 200-day, and 52-week technical levels?

ELTX last traded at $1.68 (-4.00% on volume of 183,894 shares), positioning the stock -16.42% below its 50-day simple moving average ($2.01) and -75.00% below its 200-day simple moving average ($6.72). Across its 52-week range of $1.44 to $16.00, ELTX sits at the 1.6% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.47 to $1.89).

Direct Sub-Reports: ELTX RQD Cockpit ELTX 12M Forecast ELTX Earnings & Move ELTX Dividends & DRIP ELTX Insiders & 13F ELTX Whale Options ELTX Profit Sankey ELTX News & Why

ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ELTX — Elicio Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:47:08Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ELTX scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 5.75). Taken together, the weakest pillars are the cash engine and the smart-money signals, both of which sit at or near the bottom of their ranges. For a prospective investor, the implication is that the stock currently lacks internal cash generation, and the rating's inputs do not offer strong external validation to offset that. The forensic balance-sheet reading, while still weak, is the least negative of the five, which suggests the risk profile is driven more by operating burn than by leverage alone. Any upside case would need to rest on events outside the financial statements, such as clinical or regulatory developments, rather than on improving fundamentals visible in this data.

Business

Elicio Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue for FY 2025 and FY 2024 is — in each period per the SEC financials, indicating no reported revenue in those years. — for how the company monetizes its activities.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the most prominent items are as follows:

A Nature Medicine simultaneous publication tied to Phase 2 AMPLIFY-7P results presented at ESMO Congress 2026 (marked YELLOW, MARKET WIRE).
An announcement that Phase 2 AMPLIFY-7P results will be presented at the SITC 2026 Annual Meeting (YELLOW, MARKET WIRE).
Two short-term price reports showing gains to $1.89 and $1.83 (one marked GREEN, CATALYST).
A stock price prediction piece (YELLOW, MARKET WIRE).

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The clinical presentations are the primary catalysts; the price-move items are market commentary. Risk watch items include the 52-week range of $1.44 to $16, indicating a large drawdown, and the price move of -5.4% in the latest session per the market data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

— The Butterfly Supply-Chain Graph lists no supply chain and no butterfly links, so upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the provided sources.

Open Questions

What are the specific products, clinical programs, and partners of Elicio Therapeutics, and what is the status of the AMPLIFY-7P program?
What is the company's cash runway given FY 2025 cash of $18.6M against FY 2025 FCF of $-37.0M?
What are the terms, timing, and dilution implications of any financing needed to fund operations?
What caused debt to decline from $20.0M to $9.4M, and what are the associated covenants or maturities?
Why are P/E, EPS, and EV/EBITDA unavailable, and how would valuation be assessed for a company without reported revenue?

ELTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Elicio Therapeutics Inc. (ELTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ELTX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 19h ago

Elicio Therapeutics, Inc. (ELTX) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE marketscreener.com • 22h ago

Elicio Therapeutics, Inc. Presents Late-Breaking Phase 2 AMPLIFY-7P Results At ESMO Congress 2026 And Announces Simultaneous Publication In Nature Medicine

marketscreener.com report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Manila Times • 1d ago

Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting

The Manila Times report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

ELTX Stock: Elicio Therapeutics Gains 4.42% to $1.89, Pressing Toward Resistance - Bollinger Expansion

https://www.dars.gov.et/ report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

Elicio Therapeutics (ELTX) Jumps 7.65% to $1.83 as Buyers Test $1.92 Resistance - Market Leader Picks

https://www.dars.gov.et/ report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Elicio Therapeutics, Inc. (ELTX) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 5d ago

Elicio Therapeutics To Demonstrate Data Of Two Poster Presentations For Its Phase 2 AMPLIFY-7P Trial Of Camupepimut , Expanded Antigen-Agnostic Intratumoral Application Of AMP-Adjuvant Platform At Society For Immunotherapy Of Cancer's Annual Meeting

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 10d ago

Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine

Multiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P), including patients with and without detectable baseline ctDNA.Encouraging disease-free survival outcomes were observed in both ctDNA-negative (HR

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ELTX Bull vs. Bear Conversation Board — What's Your Call at $1.68?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELTX 🐻 33% BEARISH CONVICTION

AL AlphaFlow_Cap Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $2.03 (+20.8%)

📌 Pinned Debate

Phase 2 AMPLIFY-7P results are slated for presentation at ESMO Congress 2026 and SITC 2026 with a simultaneous Nature Medicine publicat

Phase 2 AMPLIFY-7P results are slated for presentation at ESMO Congress 2026 and SITC 2026 with a simultaneous Nature Medicine publication, offering a potential clinical catalyst.. When you look under the hood at ELTX, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $16.00. My 12M target is $2.03.

SectorRotator 🐂 BULL

@AlphaFlow_Cap Agree on the RQD 28/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.68 and keeping dry powder in case we test $1.56.

RE RedlineAuditor Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1.33 (-20.8%)

Spot @ $1.68

With FY 2025 FCF of $-37.0M against $18.6M in cash and zero reported revenue, the company's cash engine scores 6/20 in the RQD rating.

Fading this rally in ELTX at $1.68. With FY 2025 FCF of $-37.0M against $18.6M in cash and zero reported revenue, the company's cash engine scores 6/20 in the RQD rating.. With a beta of 1.0 and the stock sitting at $1.68 (52-wk range $1.44–$16.00), the easy multiple expansion is already priced in.